Literature DB >> 15016345

The pathogenesis of fibrosis and renal disease in scleroderma: recent insights from glomerulosclerosis.

Sungchun Lee1, Sohee Lee, Kumar Sharma.   

Abstract

Acute and chronic renal diseases remain common complications of systemic sclerosis. Although treatment for acute scleroderma renal crisis may arrest the rapid progression of renal disease, many patients develop persistent renal dysfunction. Based on recent insights gained from progressive renal diseases of diverse etiologies, novel approaches to understanding the pathobiology of scleroderma renal disease may be applicable. Key factors involved in progression of renal disease include accumulation of extracellular matrix in the glomerular and tubulointerstitial compartments, epithelial to mesenchymal transformation, and vascular changes. The relevant factors mediating these events include the renin-angiotensin system, the profibrotic growth factors, transforming growth factor-beta and connective tissue growth factor, and reactive oxygen species. Much of the molecular details of the role of these factors have been revealed and promise to alter the practice of therapy of progressive renal disease.

Entities:  

Mesh:

Year:  2004        PMID: 15016345     DOI: 10.1007/s11926-004-0059-3

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  49 in total

Review 1.  Scleroderma renal crisis.

Authors:  Virginia D Steen
Journal:  Rheum Dis Clin North Am       Date:  2003-05       Impact factor: 2.670

Review 2.  TGF-beta in kidney fibrosis: a target for gene therapy.

Authors:  W A Border; N A Noble
Journal:  Kidney Int       Date:  1997-05       Impact factor: 10.612

3.  Effect of anti-transforming growth factor-beta antibodies in cyclosporine-induced renal dysfunction.

Authors:  M Islam; J F Burke; T A McGowan; Y Zhu; S R Dunn; P McCue; J Kanalas; K Sharma
Journal:  Kidney Int       Date:  2001-02       Impact factor: 10.612

4.  Hemodynamic effects of Bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension.

Authors:  D J Williamson; L L Wallman; R Jones; A M Keogh; F Scroope; R Penny; C Weber; P S Macdonald
Journal:  Circulation       Date:  2000-07-25       Impact factor: 29.690

5.  Hepatocyte growth factor suppresses interstitial fibrosis in a mouse model of obstructive nephropathy.

Authors:  S Mizuno; K Matsumoto; T Nakamura
Journal:  Kidney Int       Date:  2001-04       Impact factor: 10.612

6.  Is Smad3 a major player in signal transduction pathways leading to fibrogenesis?

Authors:  A B Roberts; E Piek; E P Böttinger; G Ashcroft; J B Mitchell; K C Flanders
Journal:  Chest       Date:  2001-07       Impact factor: 9.410

7.  Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice.

Authors:  F N Ziyadeh; B B Hoffman; D C Han; M C Iglesias-De La Cruz; S W Hong; M Isono; S Chen; T A McGowan; K Sharma
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

8.  Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.

Authors:  Sharon E Maynard; Jiang-Yong Min; Jaime Merchan; Kee-Hak Lim; Jianyi Li; Susanta Mondal; Towia A Libermann; James P Morgan; Frank W Sellke; Isaac E Stillman; Franklin H Epstein; Vikas P Sukhatme; S Ananth Karumanchi
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

9.  Involvement of transforming growth factor-beta in regulation of calcium transients in diabetic vascular smooth muscle cells.

Authors:  Kumar Sharma; Leo Deelman; Muniswamy Madesh; Bernd Kurz; Emilio Ciccone; Senthuran Siva; Taishan Hu; Yanqing Zhu; Lewei Wang; Robert Henning; Xinliang Ma; Gyorgy Hajnoczky
Journal:  Am J Physiol Renal Physiol       Date:  2003-07-22

Review 10.  Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases.

Authors:  H Matsubara
Journal:  Circ Res       Date:  1998 Dec 14-28       Impact factor: 17.367

View more
  7 in total

1.  Overexpression of the FoxO1 Ameliorates Mesangial Cell Dysfunction in Male Diabetic Rats.

Authors:  Guijun Qin; Yingni Zhou; Feng Guo; Lei Ren; Lina Wu; Yuanyuan Zhang; Xiaojun Ma; Qingzhu Wang
Journal:  Mol Endocrinol       Date:  2015-06-01

2.  Vascular involvement in systemic sclerosis (scleroderma).

Authors:  Debendra Pattanaik; Monica Brown; Arnold E Postlethwaite
Journal:  J Inflamm Res       Date:  2011-07-26

Review 3.  Targeting Systemic Sclerosis from Pathogenic Mechanisms to Clinical Manifestations: Why IL-6?

Authors:  Anca Cardoneanu; Alexandra Maria Burlui; Luana Andreea Macovei; Ioana Bratoiu; Patricia Richter; Elena Rezus
Journal:  Biomedicines       Date:  2022-01-29

4.  Anti-Apoptosis of Podocytes and Pro-Apoptosis of Mesangial Cells for Telmisartan in Alleviating Diabetic Kidney Injury.

Authors:  Xin Wei; Yabin Ma; Ya Li; Wenzhao Zhang; Yuting Zhong; Yue Yu; Li-Chao Zhang; Zhibin Wang; Ye Tu
Journal:  Front Pharmacol       Date:  2022-04-19       Impact factor: 5.988

5.  Fenofibrate attenuated glucose-induced mesangial cells proliferation and extracellular matrix synthesis via PI3K/AKT and ERK1/2.

Authors:  Rui Zeng; Yan Xiong; Fengming Zhu; Zufu Ma; Wenhui Liao; Yong He; JinSeng He; Wei Li; Juan Yang; Qian Lu; Gang Xu; Ying Yao
Journal:  PLoS One       Date:  2013-10-09       Impact factor: 3.240

Review 6.  A Potential Link Between Oxidative Stress and Endothelial-to-Mesenchymal Transition in Systemic Sclerosis.

Authors:  Duong Thi Bich Thuan; Hatem Zayed; Ali H Eid; Haissam Abou-Saleh; Gheyath K Nasrallah; Arduino A Mangoni; Gianfranco Pintus
Journal:  Front Immunol       Date:  2018-09-19       Impact factor: 7.561

7.  Clinical trial for conventional medicine integrated with traditional Chinese medicine (TCM) in the treatment of patients with chronic kidney disease.

Authors:  Yi Xi; Xun Lu; Like Zhu; Xiaoyi Sun; Yuqin Jiang; Weiming He; Minggang Wei
Journal:  Medicine (Baltimore)       Date:  2020-05-22       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.